Reducing Sitting Time in People with Kidney Disease and Obesity
Tests ways to help adults with kidney disease and obesity sit less and move more.
Key facts
- Who runs it
- Srinvasan Beddhu
- Where
- Salt Lake City and Stanford, United StatesSee the 2 sites
- Trial code
- Registry title
- Sit Less, Interact and Move More (SLIMM) 2 Study
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 156 people, planned
- Started
- 1 Dec 2021
- Expected to end
- 31 Mar 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- SLIMM
- Standard Resistance Training
- Guided Resistance Training
- Placebo
- Semaglutide
- Record updated
- 27 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic kidney disease (not on dialysis) who can do resistance training. It tests ways to sit less and move more.
- Age
- 20 years or older
- Sex
- All sexes can join.
- Disease stage
- Chronic kidney disease with an eGFR of 20 to <60 mL/min/1.73m^2.
- Earlier treatment
- Cannot have used any GLP-1 receptor agonist in the 30 days before screening. Cannot have had bariatric surgery.
- Biomarker or test result
- eGFR 20 to <60 mL/min/1.73m^2. Sitting time above 25 min/hr at baseline, measured by accelerometer.
Main reasons for not taking part
- Type 1 diabetes
- Dialysis or kidney transplant expected to start within 6 months
- History of pancreatitis, gastroparesis or paralytic ileus
- Pregnant or incarcerated
- Uses a mobility aid or supplemental oxygen during the day
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to <60 mL/min/1.73m\^2
- Able to perform resistance training
- Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop
Who cannot take part
- Previous bariatric surgery
- Anticipated start of dialysis or kidney transplantation within 6 months
- Enrolled in interventional trials using drugs or devices
- Use of any GLP-1 receptor agonist within 30 days prior to screening
- Type 1 Diabetes
- History of gastroparesis or paralytic ileus
- Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma
- Medical condition likely to limit survival to less than 1 year
- Known or suspected hypersensitivity to tegaderm
- Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure
- Presence of metastatic cancer
- At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer
- Any factors judged by the investigator or study team to likely limit adherence to interventions
- Vulnerable populations- pregnant or incarcerated
- Not able to undergo informed consent
- Recent hospitalizations or major interventional procedures done within the past 60 days
- Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system)
- Current use of mobility aid(s)
- Living in the same household of a participant already enrolled in the study
Where in United States
- University of UtahSalt Lake City, United StatesContact: Judy CarleTaking people
- Stanford UniversityStanford, United StatesContact: Edison LeeTaking people
About the trial
What the trial wants to find out
* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. * Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2. * This NIH funded study is conducted at the University of Utah and Stanford University. * The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.
The 3 groups in the trial
- SLIMM + Standard RT + PlaceboPlacebo, for comparison
SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, standard-of-care resistance training and oral placebo
Treatment: SLIMM, Standard Resistance Training, and Placebo
- SLIMM + Guided RT + PlaceboExisting treatment, for comparison
SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral placebo
Treatment: SLIMM, Guided Resistance Training, and Placebo
- SLIMM + Guided RT + SemaglutideTreatment being tested
SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral semaglutide
Treatment: SLIMM, Guided Resistance Training, and Semaglutide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Sit Less, Interact and Move More (SLIMM) 2 Study
- Plain-language title
- Reducing Sitting Time in People with Kidney Disease and ObesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 27 July 2026